A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Daratumumab (Primary) ; Bortezomib; Cyclophosphamide; Cyclophosphamide; Dexamethasone; Dexamethasone
- Indications Amyloidosis
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 17 Oct 2017 Status changed from not yet recruiting to recruiting.
- 27 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 2 Oct 2017.
- 27 Jun 2017 Status changed from planning to not yet recruiting.